{
  "nccn_ovariancancer_v3_2025__v00000000|18": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 18,
    "text": "f See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\ni Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude\nof benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include measure of HR (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.",
    "metadata": {
      "rank": 5,
      "score": 0.6238511800765991
    },
    "cached_at": "2026-01-21T17:35:36.171218"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|10": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 10,
    "text": "with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.",
    "metadata": {
      "rank": 5,
      "score": 0.6210723519325256
    },
    "cached_at": "2026-01-21T18:41:44.026145"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|11": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 11,
    "text": "cytoreduction\no Residual ChT toxicity\no The patient’s general condition and preferences\n\u0004 Patients with ﬁrst relapse of ovarian cancer after >6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].",
    "metadata": {
      "rank": 3,
      "score": 0.6398172378540039
    },
    "cached_at": "2026-01-21T08:27:17.062915"
  },
  "nccn_ovariancancer_v3_2025__v00000000|15": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 15,
    "text": "n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive",
    "metadata": {
      "rank": 1,
      "score": 0.6738948225975037
    },
    "cached_at": "2026-01-21T17:39:59.458031"
  },
  "nccn_ovariancancer_v3_2025__v00000000|14": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 14,
    "text": "n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using\nthe most recent available tumor tissue. Tumor molecular analysis is recommended to\ninclude, at a minimum, tests to identify potential benefit from targeted therapeutics that\nhave tumor-specific or tumor-agnostic benefit including, but not limited to, HER2 status\n(by IHC), BRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and\nNTRK if prior testing did not include these markers. More comprehensive testing may be\nparticularly important in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if\nnot previously done.\nBest supportive care (See NCCN Guidelines for Palliative Care)\nand/or\nRecurrence therapy (OV-C, 9 of 12)n,jj,kk\nTHERAPY FOR PERSISTENT DISEASE OR RECURRENCEn,gg,hh,ii\nff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.",
    "metadata": {
      "rank": 3,
      "score": 0.6678934693336487
    },
    "cached_at": "2026-01-21T17:39:59.464388"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|4": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 4,
    "text": "procedures.20\nSystemic therapy\nAdjuvant platinum-based ChT signiﬁcantly prolongs OS and\nPFS in patients with early-stage EOC, as demonstrated in\nthe joint analysis of ACTION and ICON1 trials and a\nFigure 1. Management of early EOC (FIGO stage I-II).\nSee Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2023.07.011, for a summary of the beneﬁt of adjuvant systemic therapy for early EOC (FIGO\nI-II stage).\nPurple: general categories or stratiﬁcation; red: surgery; blue: systemic anticancer therapy; white: other aspects of management; dashed lines: optional therapy.\nCCC, clear-cell carcinoma; ChT, chemotherapy; EC, endometrioid carcinoma; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics;\nHGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; MC, mucinous carcinoma.\nAnnals of Oncology\nA. González-Martín et al.\n836\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34",
    "metadata": {
      "rank": 5,
      "score": 0.5540302991867065
    },
    "cached_at": "2026-01-20T20:53:30.621165"
  },
  "nccn_ovariancancer_v3_2025__v00000000|22": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 22,
    "text": "Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\n• For platinum-sensitive disease, see OV-C (8 of 12)\n• For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRα (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due",
    "metadata": {
      "rank": 4,
      "score": 0.6233800649642944
    },
    "cached_at": "2026-01-21T18:41:44.024236"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|7": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 7,
    "text": "A descriptive OS analysis of SOLO1 at 7-year follow-up60\nand the ﬁnal OS analysis of PAOLA-161 have shown a beneﬁt\nin OS for olaparib in patients with BRCA1/2-mutated tu-\nmours and olaparibebevacizumab in patients with HRD-\npositive tumours regardless of BRCA1/2-mut status (see\nSupplementary Material Section 3, available at https://doi.\norg/10.1016/j.annonc.2023.07.011).\nNon-high-grade serous advanced ovarian cancer. Pacli-\ntaxelecarboplatin is the standard systemic ChT used in\nLGSC, CCC and MC. Multiple retrospective studies, however,\nshowed lower response rates in these histotypes compared\nwith HGSC.62-64 Bevacizumab has shown activity in all his-\ntotypes including those less chemoresponsive, e.g. LGSC or\nCCC.49 The majority of LGSCs have high expression of es-\ntrogen receptor (ER) and progesterone receptor (PgR);\nretrospective studies suggest a possible therapeutic value of\nhormone therapy in the maintenance of newly diagnosed\nadvanced LGSC.65 This intervention is currently under\nevaluation in a prospective RCT (NCT04095364).\nRecommendations\n\u0004 Patients with advanced EOC should be evaluated for PCS\nby a specialised team, with the aim of achieving",
    "metadata": {
      "rank": 5,
      "score": 0.6144667267799377
    },
    "cached_at": "2026-01-19T06:58:48.805009"
  },
  "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000|10": {
    "doc_id": "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000",
    "page": 10,
    "text": "platinum-based ChT followed by niraparib or rucaparib if\nin CR/PR/NED [I, B].\nConsensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36\nvoters)\nRecommendation 13.9: When used as maintenance in\npatients in CR/PR/NED to platinum-based ChT, olaparib\n(alone or in combination with bevacizumab) and rucaparib\nare recommended for 2 years, and niraparib is recom-\nmended for 3 years [I, A].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\n14. How should older/frail patients with tubo-ovarian\ncarcinoma be investigated and treated?\nOlder patients are under-represented in clinical trials due\nto their poor performance status (PS) and comorbidities,88\nand their outcomes are poorer.89 Geriatric assessment\ngathers information on functional, mental and nutritional\nstatus, emotional conditions and social support.90 Vulner-\nability scores have been validated in clinical trials.90,91\nSurgery, frequently carried out in an emergency context\nand in unspecialised centres, is often incomplete, with\nhigher\npost-operative\ncomplications.92\nChT\nmay\nbe\nunderutilised.93,94\nRecommendation 14.1: Patients should not be excluded\nfrom diagnostic procedures, clinical trials and speciﬁc",
    "metadata": {
      "rank": 5,
      "score": 0.6232171654701233
    },
    "cached_at": "2026-01-19T08:00:34.696914"
  },
  "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000|17": {
    "doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000",
    "page": 17,
    "text": "17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).",
    "metadata": {
      "rank": 2,
      "score": 0.6264339089393616
    },
    "cached_at": "2026-01-21T18:41:44.020045"
  },
  "esmo_cpg_nonepithelialovarian_2018__v00000000|13": {
    "doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000",
    "page": 13,
    "text": "nately, none of them has been compared with BEP in randomised\ntrials. A phase II Gynecologic Oncology Group (GOG) trial\nreported high activity with an acceptable toxicity proﬁle for a\ncarboplatin–etoposide combination in the adjuvant setting\nof completely resected stages I–III dysgerminomas [40].\nDysgerminomas are very sensitive to RT; however, its use is lim-\nited to selected cases because of the negative impact on fertility.\nIn patients with platinum-sensitive relapse (progression\n> 4–6 weeks after completion of ChT), ifosfamide/platinum (IP)\nwith or without paclitaxel (P) should be considered as second-\nline treatment [IV, C] [41]. Further active ChT regimens include:\nvinblastine/ifosfamide/cisplatin (VeIP) and cisplatin/vinblastine/\nbleomycin (PVB) [IV, C] [42]. Patients resistant to a cisplatin-\nbased combination may receive vincristine/actinomycin D/cyclo-\nphosphamide (VAC) or paclitaxel/gemcitabine or gemcitabine/\noxaliplatin as salvage therapy [IV, C].\nAlthough there is a role for ASCT in relapsed testicular cancer, it\nis not the standard of care for women with relapsed or recurrent\nmalignant ovarian GCTs and its role remains undeﬁned because of",
    "metadata": {
      "rank": 3,
      "score": 0.6473987698554993
    },
    "cached_at": "2026-01-21T17:16:29.952857"
  },
  "nccn_ovariancancer_v3_2025__v00000000|11": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 11,
    "text": "4. \u0007C/A/P CT or MRI with contrast, PET/CT (skull base to mid-thigh), or PET as\nindicated.\nx No definitive evidence of disease.\nGrade 2 endometrioid\nGrade 3 endometrioid/\nhigh-grade serous\ncarcinomat\nPlatinum-based\nchemotherapy\n(see primary\nregimens for stage\nII–IV disease [OV-C,\n6 of 12])n,v\nPRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPYv\nProvide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n• See NCCN Guidelines\nfor Palliative Care\n• See NCCN Guidelines\nfor Survivorship\n• Provide symptom\nmanagement and\nbest supportive care.\nRefer for palliative\ncare assessment, if\nappropriate.\n\u0017See NCCN Guidelines\nfor Palliative Care\n\u0017See NCCN Guidelines\nfor Survivorship\nLCOC-1\nLess common ovarian cancers (LCOC), any stageo,u\nComplete\nResponse\n(CR)x/Partial\nResponse (PR)\nStable disease\nor progression\nTherapy for Persistent\nDisease or Recurrence\n(OV-7)\nImaginga\nas clinically\nindicated:\neg, C/A/P CT, chest\nCT, A/P MRI, PET/\nMRI, PET/CT (skull\nbase to mid-thigh)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.",
    "metadata": {
      "rank": 5,
      "score": 0.6285762190818787
    },
    "cached_at": "2026-01-21T08:19:53.634940"
  },
  "nccn_ovariancancer_v3_2025__v00000000|6": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 6,
    "text": "resected, if possible. Removal of lymph nodes noted to have potential metastasis at the time of initial diagnosis should be considered, even if not\ncurrently suspicious or enlarged.\nOV-A (4 of 4)\n• Special Circumstances, bullet 1, sub-bullet, second sentence added: Consider endometrial sampling to exclude synchronous primary or hyperplasia.\nOV-B (2 of 3)\n• Less Common Ovarian Cancers (LCOC)\n\u0017Bullet 3, last sentence added: Features favoring primary ovarian carcinoma versus metastasis are: unilateral, \"expansile\" pattern of invasion, complex\npapillary pattern, size >10 cm, smooth external surface, microscopic cystic glands, necrotic luminal debris, mural nodules, and accompanying\nteratoma, adenofibroma, endometriosis, or Brenner tumor.\nOV-B (2 of 3)(continued)\n\u0017Bullet 4 added: Most early stage invasive mucinous ovarian cancers have an expansile pattern of growth characterized by complex glandular,\npapillary and/or cribriform architecture with a labyrinthine or anastomosing pattern and little or no intervening stroma. About 20% have an infiltrative",
    "metadata": {
      "rank": 4,
      "score": 0.6036849021911621
    },
    "cached_at": "2026-01-20T18:58:18.837012"
  },
  "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000|6": {
    "doc_id": "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000",
    "page": 6,
    "text": "carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneﬁt for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].",
    "metadata": {
      "rank": 3,
      "score": 0.6237844228744507
    },
    "cached_at": "2026-01-21T18:41:44.022357"
  },
  "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000|16": {
    "doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000",
    "page": 16,
    "text": "16\n•\t Granulosa cell tumours stage IA and IC1;\n•\t Sertoli-Leydig cell well-and-moderately differentiated tumours stage IA;\n•\t Low-grade serous and low grade endometrioid carcinomas stage IA and IC1;\n•\t High-grade serous carcinoma stage IA;\n•\t Mucinous carcinoma expansile subtype stage IA and IC1;\n•\t Mucinous carcinoma infiltrative stage IA;\n•\t Clear-cell carcinoma stage IA and IC1.\nB\nUnfavourable oncologic selection criteria for ovarian preservation\nOne of the following criteria should be met:\n•\t Invasive epithelial ovarian tumours stage IB and II–IV;\n•\t Low-grade serous carcinoma stage IC3;\n•\t Low-grade endometrioid carcinoma stage IC3;\n•\t High-grade serous and high-grade endometrioid carcinomas stage IC3;\n•\t Clear cell carcinoma stage IC3;\n•\t Mucinous carcinoma infiltrative stage IC3;\n•\t Small-cell carcinoma hyper calcaemic type;\n•\t Granulosa cell tumour stage IB and II–IV;\n•\t Sertoli-Leydig cell tumours well-and-moderately differentiated at stages\n\nIB and IC2–IV, and poorly differentiated at all stages.\nB\nOncologic selection criteria acceptable in selected cases\nOne of the following criteria should be met:\n•\t Low-grade serous and low-grade endometrioid carcinomas stage IC2;",
    "metadata": {
      "rank": 4,
      "score": 0.5006415247917175
    },
    "cached_at": "2026-01-21T08:31:44.402486"
  },
  "nccn_ovariancancer_v3_2025__v00000000|36": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 36,
    "text": "FRα (FOLR1), RET, and NTRK if prior testing did not include\nthese markers. More comprehensive testing may be particularly\nimportant in less common histologies with limited approved\ntherapeutic options. It is recommended that such testing be\nperformed on the most recent available tumor tissue.\n\u0017Molecular analyses may be performed on circulating tumor\nDNA (ctDNA or liquid biopsy) when tissue-based analysis is not\nclinically feasible.\n\u0017Validated molecular testing should be performed in a CLIA-\napproved facility.",
    "metadata": {
      "rank": 5,
      "score": 0.5004697442054749
    },
    "cached_at": "2026-01-21T08:31:44.403948"
  },
  "nccn_ovariancancer_v3_2025__v00000000|2": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 2,
    "text": "MD Anderson Cancer Center\n*Heidi J. Gray, MD Ω\nFred Hutchinson Cancer Center\nRachel Grisham, MD Ω\nMemorial Sloan Kettering Cancer Center\nNCCN\nEmily Kovach\nSwathi Ramakrishnan, PhD\nNCCN Guidelines Panel Disclosures\nΩ Gynecology oncology\n‡ Hematology/\nHematology oncology\nÞ Internal medicine\n† Medical oncology",
    "metadata": {
      "rank": 4,
      "score": 0.5090075135231018
    },
    "cached_at": "2026-01-20T20:47:09.499715"
  },
  "nice_ng241_geneticrisk_ovarian_2024__v00000000|4": {
    "doc_id": "nice_ng241_geneticrisk_ovarian_2024__v00000000",
    "page": 4,
    "text": "Pathology protocol for handling specimens from risk-reducing surgery ........................................ 63\nHormone replacement therapy after risk-reducing surgery ............................................................. 64\nContext ......................................................................................................................................... 66\nFinding more information and committee details ..................................................................... 67\nUpdate information ..................................................................................................................... 68\nOvarian cancer: identifying and managing familial and genetic risk (NG241)\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\nconditions#notice-of-rights).\nPage 4 of\n68",
    "metadata": {
      "rank": 5,
      "score": 0.5078673362731934
    },
    "cached_at": "2026-01-20T20:47:09.500640"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|8": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 8,
    "text": "cancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a\ntreatment for patients with recurrent disease (Figure 3).\nSystemic therapy of recurrent disease is based on plat-\ninum-containing\nor\nnon-platinum-containing\nregimens.\nThere are currently no molecular biomarkers to predict ef-\nﬁcacy of platinum rechallenge. The deﬁnition of platinum\nsensitivity based on a 6-month cut-off of treatment-free\ninterval from last platinum (TFIp) was challenged during\nthe Fifth Gynecological Cancer InterGroup (GCIG) Ovarian\nCancer Consensus Conference and later discontinued in\nclinical practice following the 2018 ESMOeEuropean Soci-\nety of Gynaecological Oncology (ESGO) Consensus Confer-\nence, as many factors may inﬂuence TFIp (e.g. the\nfrequency of follow-up and interval of diagnostic tests) and\nthe response to platinum (i.e. histotype or BRCA1/2-mut\nstatus).32,66 Not all patients with TFIp >6 months respond\nto platinum (objective response rate 47.2%-66%),32 and\nconversely, platinum-based combinations have demon-\nstrated activity in patients with TFIp <6 months.67\nSurgery for relapse",
    "metadata": {
      "rank": 1,
      "score": 0.6632776856422424
    },
    "cached_at": "2026-01-21T07:12:46.237146"
  },
  "nccn_ovariancancer_v3_2025__v00000000|9": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 9,
    "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nIDS with completion\nhysterectomy/BSOj,k and\ncytoreduction. Consider\nHIPEC.j\nor\nContinue current therapy (for\na total of at least 6 cycles)n\nor\nTherapy for Persistent\nDisease or Recurrence (OV-7)\nOV-2\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\ng Germline and somatic BRCA1/2 status informs maintenance therapy.\nh In the absence of a BRCA1/2 mutation, HRD status may provide information on the\nmagnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include\nmeasure of HR (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:",
    "metadata": {
      "rank": 2,
      "score": 0.6027355790138245
    },
    "cached_at": "2026-01-21T03:12:29.998478"
  },
  "nccn_ovariancancer_v3_2025__v00000000|26": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 26,
    "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Sex Cord-Stromal Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-11\nCLINICAL PRESENTATION/\nDIAGNOSIS\nADJUVANT\nTREATMENT\nRECURRENCE\nTHERAPY\nMalignant sex\ncord-stromal\ntumorsa\nDisease\nclinically\nconfined\nto ovary,\nfertility\ndesired\nAll others\nStage I\nLow risk\nStage II–IV\nFertility-\nsparing\nsurgery with\ncomplete\nstagingc,d,bb\nStage I, high risk\n(eg, ruptured\nstage IC or poorly\ndifferentiated stage I)\nor\nIntermediate risk\n(eg, heterologous\nelements)\nObservecc (category 2B)\nor\nConsider platinum-based\nchemotherapydd,ee\n(category 2B)\nPlatinum-based\nchemotherapydd,ee\nor\nRT for limited\ndisease (category 2B)\nIf clinical relapse:\nConsider\nsecondary\ncytoreductive\nsurgery\nor\nRecurrence\ntherapyee,ff\nComplete\nstagingc,d,bb\nSurveillance\n(LCOC-B)\nObservecc\na WHO Histologic Classification (OV-E).\nc Principles of Surgery (OV-A).",
    "metadata": {
      "rank": 3,
      "score": 0.6016931533813477
    },
    "cached_at": "2026-01-21T03:12:29.999991"
  },
  "nccn_ovariancancer_v3_2025__v00000000|28": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 28,
    "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nMalignant Germ Cell Tumors\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nLCOC-13\nADJUVANT TREATMENT\nMONITORING/\nFOLLOW-UP\nTHERAPY FOR RECURRENT/\nPERSISTENT DISEASEff\nPATHOLOGIC\nDIAGNOSISa\nAny stage\nembryonal\ntumorii\nor\nAny stage\nendodermal\nsinus tumor (yolk\nsac tumor)ii\nor\nStage II–IV\ndysgerminoma\nor\nStage I, grade\n2 or 3 or Stage\nII–IV immature\nteratoma\nor\nAny stage\nnongestational\nchoriocarcinoma\nStage I\ndysgerminomaii\nor\nStage I, grade 1\nimmature\nteratomaii\nChemotherapyjj\nLCOC-14\nC/A/P CTp or MRI as\nclinically indicated\nResidual\ntumor on\nradiographic\nimaging;\nmarkers\nnormalkk\nPersistently\nelevated markerskk\nwith definitive\nresidual disease\nBiopsy\nor\nConsider\nsurgical\nresection\nor\nObserve\n(Surveillance\n[LCOC-B])\nNecrotic\ntissue\nBenign\nteratoma\nResidual\nmalignancy\nObserve\nSurveillance (LCOC-B)\nComplete\nclinical\nresponse\nTIP (paclitaxel/ifosfamide/\ncisplatin)",
    "metadata": {
      "rank": 4,
      "score": 0.5975537896156311
    },
    "cached_at": "2026-01-21T03:12:30.001434"
  },
  "nccn_ovariancancer_v3_2025__v00000000|10": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 10,
    "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nOV-3\nDIAGNOSIS BY PREVIOUS SURGERY\nFINDINGS\nPatient\nreferred\nwith newly\ndiagnosed\novarian\ncancer,\nincluding\nless common\novarian\ncancers\n(LCOCs),\nafter recent\nsurgical\nprocedure\nConsider surgical stagingj,k (if not\npreviously done) if considering\nobservation or to inform systemic\ntherapy decisionss\nTumor\ncytoreductive\nsurgeryj,k\nNeoadjuvant Therapy (OV-2)\nSuspect\nresectable\nresidual disease\nSuspect\nunresectable\nresidual diseaser\nAdjuvant\nTherapy\n(OV-4)\na CT is performed with oral and iodinated IV contrast (unless contraindicated due to\nanaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI is\nperformed with gadolinium-based contrast agents (unless contraindicated due to",
    "metadata": {
      "rank": 5,
      "score": 0.590817928314209
    },
    "cached_at": "2026-01-21T03:12:30.002872"
  },
  "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000|8": {
    "doc_id": "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000",
    "page": 8,
    "text": "[III, B].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\nRecommendation 11.7: Contrast-enhanced CT, MRI and\nPETeCT with a structured radiology report are considered\nas options for the initial evaluation of patients with\nadvanced ovarian carcinoma [III, A]. US by an expert so-\nnographer may be used to assess tumour extent and\nresectability in the pelvis and abdominal cavity [III, C].\nJ. A. Ledermann et al.\nAnnals of Oncology\nVolume 35",
    "metadata": {
      "rank": 3,
      "score": 0.6316177845001221
    },
    "cached_at": "2026-01-21T08:19:53.631548"
  },
  "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000|14": {
    "doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000",
    "page": 14,
    "text": "14\nUnfavourable oncologic selection criteria\nAt least one of the following criteria should be met:\n•\t Any histological type other than squamous cell carcinoma and usual-type\n\nHPV-associated adenocarcinoma (mucinous-type HPV-associated carci-\n\nnomas, gastric-type cervical adenocarcinoma, mesonephric carcinoma,\n\nsmall-cell neuroendocrine carcinoma, and clear cell carcinoma;\n•\t Confirmed pelvic nodal involvement, extracervical tumour extension,\n\nevidence of tumour beyond the cervical ring, or metastasis;\n•\t The largest tumour measurement is more than 4 cm by imaging or clinical\n\nexam;\n•\t FIGO stage is IB3 or more;\n•\t Tumour cranial extent is less than 5 mm from, or involves, the internal\n\ncervical orifice or lower uterine segment by imaging;\n•\t Intraoperative frozen-section assessment of the resected cervical spe-\n\ncimen for assessing the upper resection margin reveals a positive margin\n\nfrom the internal cervical orifice with inability to achieve a wider margin;\n•\t Histologically confirmed endocervical margin, endocervical curettage\n\nabove resection, or endometrial involvement on final pathology.\nC\nB\nB\nB\nB\nB\nB\nOncologic selection criteria acceptable in selected cases",
    "metadata": {
      "rank": 2,
      "score": 0.5076438784599304
    },
    "cached_at": "2026-01-21T08:31:44.399150"
  },
  "nccn_ovariancancer_v3_2025__v00000000|13": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 13,
    "text": "the most recent available tumor tissue. Tumor molecular analysis is recommended\nto include, at a minimum, tests to identify potential benefit from targeted therapeutics\nthat have tumor-specific or tumor-agnostic benefit including, but not limited to, HER2\nstatus (by IHC), BRCA1/2, HRD status, microsatellite instability (MSI), mismatch\nrepair (MMR), tumor mutational burden (TMB), BRAF, FRα (FOLR1), RET, and NTRK\nif prior testing did not include these markers. More comprehensive testing may be\nparticularly important in LCOC with limited approved therapeutic options (OV-B).\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.",
    "metadata": {
      "rank": 3,
      "score": 0.5049008131027222
    },
    "cached_at": "2026-01-21T08:31:44.400933"
  },
  "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000|11": {
    "doc_id": "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000",
    "page": 11,
    "text": "Consensus: 100% (34) yes, 0% (0) no, 0% (0) abstain (34\nvoters)\nRecommendation 15.10: After local ablative/surgical\ntumour\nmanagement,\ncontinuation\nof\nmaintenance\ntreatment with the same regimen could be considered\n[IV, C].\nConsensus: 94% (32) yes, 3% (1) no, 3% (1) abstain (34\nvoters)\n16. What is the role of molecularly targeted therapy in\nrecurrent disease?\nThe selection of molecularly targeted therapy with\nplatinum-based\ntherapydcurrently\nbevacizumab\nor\nPARPisdis driven by biological factors, prior use of\nmolecularly targeted therapy and regulatory approvals.\nBevacizumab added to platinum-based ChT and continued\nas maintenance increases the tumour response rate and PFS\nwithout an OS beneﬁt.\nIn randomised trials, PARPis signiﬁcantly prolonged PFS in\nthe recurrent setting, when given as maintenance after\nresponse to platinum until progression or unacceptable\ntoxicity. This beneﬁt was more pronounced in patients with\na BRCA-mut but still relevant in patients with BRCA-wt tu-\nmours regardless of HRD status. Their use in recurrent dis-\nease is currently diminishing as they are now often used\nafter ﬁrst-line ChT (see Question 13). Second-line molecu-",
    "metadata": {
      "rank": 4,
      "score": 0.6259515881538391
    },
    "cached_at": "2026-01-21T17:35:36.168914"
  }
}